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Abstract
Background: First described by Ross in 1951, primary pancreatic leiomyosarcoma is a rare mesenchymal tumour of
the pancreas, with nonspecific clinical and radiological features and a poor prognosis, if unresectable.
Case report: A 60-year-old woman presented with abdominal pain. Magnetic resonance imaging (MRI) and
computed tomography (CT) scan detected a dishomogeneous egg-shaped 8-cm mass, arising from the pancreatic
head, with duodenal compression, without dilation of the Wirsung duct. 18F-FDG positron-emission tomography
(PET)-CT showed a moderate tracer uptake, and the endoscopic ultrasound (US) showed a hypoechoic lesion,
arising from the duodenal wall, suspected to be a gastrointestinal stromal tumour (GIST). CEA, CA19-9, NSE, and
chromogranin A were normal. At the surgical exploration, a 10-cm mass, adherent to the anterior aspect of the
pancreatic head, was found. The lesion was easily separable from the duodenal wall and was totally excised. The
frozen intraoperative examination showed a mesenchymal tumour, with spindle-shaped cells, suggesting that a
GIST diagnosis was likely. Postoperative course was uneventful. Histology and immunohistochemistry demonstrated
a well-differentiated leiomyosarcoma, with five to six mitotic counts per 10 high-power field (HPF) and proliferative
index (MIB-1) 10 % (grade 2 according to Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC)),
with positive smooth muscle actin, desmin, and caldesmon but negative CD117 (c-kit) and S-100. The patient is
alive and asymptomatic 19 months after surgery, without evidences of disease.
Conclusions: In the English literature, only 44 cases of primary pancreatic leiomyosarcoma have been reported. If a
pancreatic mass suspected for primary pancreatic leiomyosarcoma has no adjacent organ/vessel invasion or distant
metastases, surgical resection is the therapy of choice.
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Background
The pancreas is mainly composed of an exocrine compo-
nent, which includes acini and ducts, and an endocrine
component, the islets of Langerhans, but stroma is scant
in normal pancreas [1].
Ductal adenocarcinoma represents the most common
primary tumour arising in the pancreas. Mesenchymal
tumours may involve the pancreas, but most of them are
secondary lesions from extra pancreatic tumours. Pri-
mary mesenchymal pancreatic tumours are very rare
[2], with only about 200 cases reported in the English
literature [3].
Leiomyosarcoma is the most frequent primary malig-
nant mesenchymal tumour of the pancreas and represents
the 0.1 % of malignant pancreatic tumours [4]. Primary
pancreatic leiomyosarcoma was first described by Ross in
1951 [5], and until now, only 44 cases [3–34] have been
reported in the English literature.
We reported a case of primary pancreatic leiomyosar-
coma, which was treated with local excision.
Case presentation
A 60-year-old woman complained abdominal pain since a
few years, and she had several ultrasound (US) scans,
which resulted negative. In November 2013, an abdominal
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magnetic resonance imaging (MRI) detected a disho-
mogeneous egg-shaped mass (main diameter 8 cm), arising
from the lower part of the pancreatic head (Fig. 1a), with
normal appearance of the main pancreatic duct.
The patient did not complain anorexia or weight loss but
only dyspepsia, and physical examination was unremark-
able. The pancreatic lesion was confirmed by a computed
tomography (CT) scan. There was no evidence of invasion
of the surrounding tissues (gastroduodenal wall, retroperi-
toneal connective tissue, and common bile duct) and no
evidence of liver or lymph node involvement (Fig. 1b, 1c).
At the 18F-FDG positron-emission tomography (PET)-
CT, the lesion showed only a moderate tracer uptake,
suggesting a gastrointestinal stromal tumour (GIST)
(Fig. 1d), and at the endoscopic US, the mass was
hypoechoic and non-homogeneous, with well-defined
margins, arising from the duodenal wall, proper to a
GIST. Serum tumour markers CEA, CA19-9, NSE, and
chromogranin A were normal.
In January 2014, the patient underwent surgery. The
mass was adherent to the anterior surface of the pancreatic
head and had a vascular peduncle, a branch-side of the
anterior-inferior pancreatico-duodenal vein, that drained
into the gastro-colic trunk of Henle.
The mass compressed the third duodenal part and was
easily dissociable from the duodenal wall; then, it was to-
tally excised, including the pancreatic capsule, without
any pancreatic resections (Fig. 2a). A frozen analysis
of the specimen showed a mesenchymal tumour, with
spindle-shaped cells, suggesting that a GIST diagnosis
was likely, and intraoperative US excluded other pan-
creatic lesions.
Postoperative course was uneventful, and the patient
was discharged on postoperative day 4th.
Macroscopically, the lesion had a smooth and polylobu-
lated surface, had a fasciculated internal appearance, and
measured 10 cm as maximum diameter (Fig. 2b).
Histology revealed a well-differentiated leiomyosarcoma
(Fig. 3a), composed by spindle cells with a fasciculated
growth pattern, with five to six mitotic counts per 10
high-power field (HPF) and proliferative index (MIB-1)
10 % (grade 2 according to (FNCLCC) system [35]) (Fig. 3b).
Surgical margins were negative, and no pancreatic tissue
was included in the specimen.
Immunohistochemical analysis revealed positive smooth
muscle actin (Fig. 3c), desmin, and caldesmon but negative
CD117 (c-kit) (Fig. 3d) and S-100. Malignant epithelial
elements were not identified, excluding a sarcomatoid
carcinoma.
The patient did not receive postoperative adjuvant radio-
or chemo-therapy. She is still alive and asymptomatic after
19 months of follow up (f.u.). The last thorax-abdominal
CT performed did not detect any signs of disease recur-
rence (Fig. 4).
Fig. 1 Pre-operative imaging. MRI scan: the dishomogeneous mass, arising from the pancreatic head (a). CT scan: no evidence of invasion of the
surrounding tissues; CT venous phase: duodenal compression on the third duodenal part. (b) CT arterial phase: mass arising from the pancreatic
head (c). 18F-FDG-PET-CT: moderate tracer uptake by the pancreatic lesion (d)
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Discussion
First described by Ross in 1951 [5], primary pancreatic
leiomyosarcoma is considered to arise either from smooth
muscle cells of the pancreatic ducts or from the wall of
small intra-pancreatic vessels [7, 8, 22]. In our case, we
can only speculate if the tumour originated from the
pancreatic vessels, since we obtained negative surgical
margins and we did not have pancreatic tissue around
the excised tumour.
From our review of the English literature (Table 1)
[3–34], a pancreatic leiomyosarcoma is more common
in the fifth decade of life (range 14–87 years, median age
51 years) and in female patients (M= 20, F = 24). The
tumour size is variable, ranging from 1 to 30 cm (median
8.0 cm), and it seems to be more frequently localised in
the body-tail of the pancreas (n = 24). Abdominal pain,
weight loss, and abdominal mass are the most commonly
presenting symptoms, but these are nonspecific [36].
Fig. 2 Intraoperative findings. The mass was adherent to the anterior surface of the pancreatic head, and it was easily dissociable from the
duodenal wall (a). The 10-cm mass was totally excised. Macroscopically, it had a smooth and polylobulated surface (b)
Fig. 3 Histology and immunohistochemical analysis. Haematoxylin-eosin stain (original magnification ×50) (a). Mib1 (proliferative index) (b).
Strong immunoreactivity to smooth muscle actin (c). No immunoreactivity to CD117 (c-kit) (d)
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No serum tumour marker is expected to be positive since
the mesenchymal origin of the tumour.
Imaging studies are often unspecific [31]. In our review
[13, 14, 18, 21–24, 27, 28, 30–32, 34], pancreatic leiomyo-
sarcoma appears mainly as a heterogeneous enhancing
mass. As the tumour volume increases, haemorrhagic,
necrotic, and cystic changes, often associated to a highly ag-
gressive behaviour, can be observed, and large pancreatic
leiomyosarcoma with a cystic degeneration can be misdiag-
nosed as pseudocyst [12] or as cystadenocarcinoma [8].
In MRI, the unenhanced T1-weighted and T2-weighted
images are most useful in tumour localization [18], and
18F-FDG-PET-CT is able to identify a lesion with aggres-
sive behaviour, which may show an increased metabolic
activity [21]. CT or US-guided fine-needle aspiration
biopsy (FNAB) may help the diagnosis of those advanced
or unresectable [13].
In our case, there was no evidence of surrounding tis-
sue involvement or of distant disease localizations, and
the pancreatic mass had a dishomogeneous appearance
at MRI and CT scans, but the moderate tracer uptake
at 18F-FDG-PET-CT and the endoscopic US features
suggested a GIST diagnosis. We did not perform an EUS-
guided biopsy because with our equipment, a FNA biopsy
was not allowed. Differentiating the variety of mesenchymal
tumours by imaging is extremely difficult, and only
histology with immunohistochemical studies can define
the final diagnosis.
At the histology, a primary leiomyosarcoma of the
pancreas shows well-formed fascicles of spindle cells
with blunt-ended nuclei intersecting at vertical angles,
varying degrees of pleomorphism [23], abundant eosino-
philic cytoplasm [28], and possible increased mitotic activity
[3]. However, differential diagnosis includes other soft
tissue tumours: inflammatory myofibroblastic tumour,
non-myogenic spindle cell sarcoma (namely fibrosarcoma),
solitary fibrous tumour, liposarcoma, rhabdomyosarcoma,
undifferentiated pleomorphic sarcoma (so-called malignant
fibrous histiocytoma), malignant peripheral nerve sheath
tumour, and gastrointestinal stromal tumour [23, 28].
In immunohistochemical analysis, stromal tumours
are usually diagnosed as myogenic (i.e. leiomyomas or
leiomyosarcomas) when they are diffusely positive for
desmin or smooth muscle actin, as neurogenic when
positive for S-100 protein or as gastrointestinal stromal
tumours (GIST) when positive for CD117 (c-kit) [37].
Leiomyosarcoma usually exhibits strong activity for muscle
markers despite occasional keratin positivity. In our case,
frozen section analysis was coherent with a GIST, but the
final histological and immunohistochemical analyses dem-
onstrated a leiomyosarcoma and excluded a sarcomatoid
carcinoma and a GIST. Intraoperative frozen section is not
able to define the variety of mesenchymal neoplasm; al-
though it has a low reliability, it can exclude a carcinoma
and therefore can be helpful in the surgical strategy.
Primary leiomyosarcoma of the pancreas has a high in-
cidence of distant metastases and regional invasion, with
rare lymphatic involvement [28], which could be the key
point to differential diagnosis [36]. In our review of the
English literature, out of the 44 cases reported, 16 had
distant metastases at the time of diagnosis that mainly
occurred into the liver (n = 9) and lung (n = 2).
Sharp demarcation of the growth appearing characteristic
for this type of pancreatic neoplasm with no invasion into
the surrounding organs enabled complete excision in spite
of the large size of the tumour [20]. In this review, 28
patients benefit from a radical surgical treatment (pan-
creatico-duodenectomy and distal pancreatectomy, n = 27;
local excision, n = 1). Twenty-three patients had only
surgery and 13 of them are alive without any evidences
of disease (median f.u. 24 months, range 2–240 months).
Five patients also received adjuvant treatment (chemother-
apy and/or radiotherapy) after surgery, and only one is alive
without disease 27 months after surgery and radiotherapy
treatment for a grade 2 tumour. Ten patients had unresect-
able disease: four of them received chemotherapy (three
died of disease, mean overall survival 13 months), and six
patients untreated or had only biopsy (median survival
13 months).
Radical resection of the lesion has been reported to be
the best choice for cure of pancreatic leiomyosarcoma
[14], and the benefit of adjuvant therapy after radical
Fig. 4 Postoperative imaging. Thorax-abdominal CT scan: normal
appearance of the pancreatico-duodenal-biliary region, without any
signs of liver or lung involvement
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Table 1 Reported cases of primary pancreatic leiomyosarcoma in the English literature
Case Author Year Age, year/
sex
Site/size, cm Distant metastasis Treatment Grade IHC Outcome/follow up,
months
1 Ross [5] 1951 80/M Whole pancreas Widespread Autopsy case High n.a. DOD
2 Berman and Levene [6] 1956 47/M Head/5.5 No PD n.a. n.a. ANED/12
3 Feinberg et al [7] 1957 14/M Head/11.0 No PD Low n.a. n.a.
4–8 Baylor and Berg
(n = 5) [4]
1973 51 (median)/
3M, 2F
Body-tail/n.a. 1 localised, 1 locally
advanced, 3
disseminated
n.a. n.a. n.a. ANED (n = 1)/1; DOD
(n = 3)/14 (median)
9 Ishikawa et al [8] 1981 44/M Head/8.0 No PD/CT Low n.a. DOD/48




11 de Alava et al [10] 1993 71/M Body/3.6 No DP n.a. (+) desmin, smooth muscle actin,
vimentin; (−) AE1/AE3, CAM5.2
n.a.
12 Peskova and Fried [11] 1994 68/F Head/15.0 No PD Low n.a. ANED/36
13 Sato et al [12] 1994 53/F Body/25.0 No DP n.a. (+) desmin, smooth muscle actin;
(−) S-100, EMA
n.a.
14 Ishii et al [13] 1994 66/M Tail/4.5 Liver Non resectable/CT n.a. (+) desmin, smooth muscle actin DOD/33
15 Aranha et al [14] 1995 46/F Body/3.0 No DP/CT High (+) desmin; (−) S-100, cytokeratin,
HMB-45
DOD/9
16 Owen et al [15] 1997 40/M Head/7.0 No PD n.a. (+) desmin, smooth muscle actin ANED/120
17 Shimizu et al [16] 1997 49/F Head/15.0 Lung Non resectable/CT n.a. (+) desmin, smooth muscle actin;
(−) S-100
DOD/3
18 Chawla et al [17] 1998 45/F Head/9.2 Lung Non resectable/CT Low (+) smooth muscle actin AWD/19
19 Paciorek and Ross [18] 1998 63/F Body/2.0 Mesentery, single DP n.a. n.a. ANED/n.a.
20 Zalatnai et al [19] 1998 57/M Head/6.0 Liver Non resectable 3 (+) smooth muscle actin, SMA;
(−) S-100, desmin
DOD/7
21 Ferlan-Marolt et al [20] 2000 57/F Body-tail/12.0 No DP 2 (+) SMA; (−) desmin DOC/p.o. period
22 Machado et al [21] 2000 52/M Head/7.5 No PD Low (+) SMA; (−) S-100 ANED/24
23 Deveaux et al [22] 2001 44/F Head/5.0 No PD 1 (+focal) smooth muscle actin;
(−) S-100, keratin
ANED/48
24 Nesi et al [23] 2001 76/M Tail/8.0 No DP High (+) smooth muscle actin, SMA;
(−) desmin, CD34, cytokeratin, S-100
DOD/12
25 Aihara et al [24] 2002 25/F Body/3.5 No Local excision n.a. (+) desmin, smooth muscle actin;
(−) S-100
ANED/42
26 Komoda et al [25] 2002 52/F Head/1.5 No PD Low (+) desmin, smooth muscle actin;
(−) S-100, CD34, KIT
ANED/12













Table 1 Reported cases of primary pancreatic leiomyosarcoma in the English literature (Continued)
28 Muhammad et al [27] 2008 73/M Body/10.0 Liver Non resectable/CT Low to
intermediate
(+) desmin, smooth muscle actin;









Head (n = 7);
Tail (n = 2)/8.0 (median)




(n = 1), 3
(n = 5), 2
(n = 3)
(+) smooth muscle actin, desmin;
(−) KIT
DOD (n = 5), DOC/
Unknown (n = 4)/13
(median)
38 Riddle et al [29] 2010 83/F Tail/8.2 No DP 2 (+) smooth muscle actin, desmin,
vimentin; (−) c-kit, CD34, S-100,
pan-cytokeratin
ANED/8
39 Zhang et al [30] 2011 56/F Body-tail/13.0 No DP 2 (+) desmin, smooth muscle actin,
H-caldesmon, vimentin; (−) cytokeratin,
CD34, S-100, CD117
ANED/14
40 Hur et al [31] 2011 70/F Head/5.0 No PD 2 (+) actin, vimentin, desmin;
(−) cytokeratin, S-100, CD34, CD117
DOD/22
41 Izumi et al [32] 2011 41/F Body/4.5 No DP n.a. (+) smooth muscle actin, desmin,
vimentin
ANED/14
42 Vanderpuye et al [33] 2011 59/F Tail/24.0 Liver, transverse colon DP/ CT + RT n.a. n.a. AWD/24
43 Moletta et al [34] 2012 54/F Body and tail/13.0 Liver DP, left
hepatectomy/CT
3 (+) smooth muscle actin, desmin; (−)
cytokeratin, CD34, S-100, CD117
AWD/37
44 Kim et al [3] 2014 51/F Tail/5.5 No DP/RT 2 (+) desmin, SMA; (−) CD117, HMB45,
CD34
ANED/27
45 Present case 2014 60/F Head/10.0 No Local excision 2 (+) smooth muscle actin, desmin,
caldesmon;(−) S-100, CD117
ANED/19
ANED alive and no evidence of disease, AWD alive with disease, cm centimetres, CT chemotherapy, DOC died of other cause, DOD died of disease, DP distal pancreatectomy, IHC immunohistochemistry, n number of











pancreatectomy is still unknown [8, 14, 28]. In our case,
a local excision was performed; histology showed a grade
2 leiomyosarcoma, and the patient is alive without any
evidences of disease 19 months after surgery, without
having adjuvant therapy. In the English literature, there
is only one case reporting a local excision for a 3.5-cm
pancreatic leiomyosarcoma, alive without disease 42 months
after surgery [24].
Although tumour size is an important indicator with
regard to resectability, it does not seem to affect the
clinical course after surgical resection [23, 36]. Xu et al.
[36] showed with multivariate analysis that non-radical
resection was an independent adverse prognostic factor.
Mitotic counts of more than 10 mitoses per 10 HPF
were reported as another adverse predictor [23]. In our
review, grading (according to FNCLCC system [35]) was
available in 29 out of 44 patients, and there were 17
low-grade (or grade 1, 2) lesions and 12 high-grade (or
grade 3, 4) ones. Among the first group, 9 patients are
alive without evidence of disease (median f.u. 27 months,
range 8–240 months) and one is alive with disease after
19 months of f.u. Among the 12 high-grade patients, 9
died of disease (median overall survival 9.5 months,
range 3–98 months).
Conclusions
In the English literature only 44 cases of primary pancreatic
leiomyosarcoma have been reported. The patients present
mainly with abdominal pain, and at imaging, this tumour
rarely presents a lymphatic spread. If a pancreatic mass
suspected for primary leiomyosarcoma has no adjacent
organ/vessels invasion or distant metastases, surgical
resection is the therapy of choice. Resected patients
have longer overall survival compared to unresectable
ones. Operative specimen allows an accurate diagnosis
that depends on histological and immunohistochemical
analyses, and in unresectable cases, a biopsy is mandatory
providing to perform immunohistochemistry. Unfortu-
nately, before surgery or intraoperatively, no help comes
from FNA-cytology or frozen section analysis in order to
better distinguish among spindle cells tumours. The benefit
of adjuvant therapies is still unproven.
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